BioXcel Therapeutics Reports Second Quarter 2021 Financial Results and Recent Operational Highlights
10 août 2021 07h00 HE
|
BioXcel Therapeutics
Phase 3 study of BXCL501 for the acute treatment of agitation associated with dementia expected to begin in Q4 2021 PDUFA date of January 5, 2022 assigned to BXCL501 NDA for the acute treatment of...
BioXcel Therapeutics to Report Second Quarter 2021 Financial Results on August 10, 2021
28 juil. 2021 07h00 HE
|
BioXcel Therapeutics
NEW HAVEN, Conn., July 28, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI), a clinical-stage biopharmaceutical company utilizing artificial...
BioXcel Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference
19 juil. 2021 07h30 HE
|
BioXcel Therapeutics
NEW HAVEN, Conn., July 19, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), today announced that Dr. Vimal Mehta, Ph.D., Founder and Chief Executive...
BioXcel Therapeutics Announces Pricing of Public Offering of Common Stock
23 juin 2021 08h29 HE
|
BioXcel Therapeutics
NEW HAVEN, Conn., June 23, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company, today announced the pricing of...
BioXcel Therapeutics Announces Proposed Public Offering of Common Stock
22 juin 2021 16h01 HE
|
BioXcel Therapeutics
NEW HAVEN, Conn., June 22, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches...
BioXcel Therapeutics to Host Virtual Commercial Day on June 25, 2021
18 juin 2021 07h00 HE
|
BioXcel Therapeutics
NEW HAVEN, Conn., June 18, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial...
BioXcel Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences
26 mai 2021 07h00 HE
|
BioXcel Therapeutics
NEW HAVEN, Conn., May 26, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial...
BioXcel Therapeutics Announces FDA Acceptance for Filing of NDA for BXCL501 for the Acute Treatment of Agitation Associated with Schizophrenia and Bipolar Disorders I and II
19 mai 2021 07h00 HE
|
BioXcel Therapeutics
FDA sets PDUFA action date for January 5, 2022 If approved, BXCL501 would represent the first major advancement in the acute treatment of agitation associated with schizophrenia and bipolar disorders...
BioXcel Therapeutics Announces Presentations at the ISBD 2021 Global Annual Conference
11 mai 2021 07h00 HE
|
BioXcel Therapeutics
NEW HAVEN, Conn., May 11, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial...
BioXcel Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
10 mai 2021 07h00 HE
|
BioXcel Therapeutics
Granted FDA Breakthrough Therapy designation for BXCL501 for the acute treatment of agitation associated with dementia; registrational program expected to begin in 2H 2021 Submitted NDA to FDA for...